middle.news

How Genetic Signatures’ 63% Revenue Surge Signals a New Growth Era

10:37pm on Friday 29th of August, 2025 AEST Healthcare
Read Story

How Genetic Signatures’ 63% Revenue Surge Signals a New Growth Era

10:37pm on Friday 29th of August, 2025 AEST
Key Points
  • 63% revenue growth to $15.9 million driven by Australian respiratory sales
  • Underlying loss reduced by 28% to $12.7 million despite $7 million impairment
  • First US commercial contract secured post FDA clearance
  • Strategic partnerships with Tecan Group and Repado to develop automated platform
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Genetic Signatures (ASX:GSS)
OPEN ARTICLE